Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.

Geelen, Inge G P; Thielen, Noortje; Janssen, Jeroen J W M; Levin, Mark-David; Hoogendoorn, Mels; Visser, Otto; Cornelissen, Jan J; Westerweel, Peter E

Geelen, Inge G P; Thielen, Noortje; Janssen, Jeroen J W M; Levin, Mark-David; Hoogendoorn, Mels; Visser, Otto; Cornelissen, Jan J; Westerweel, Peter E.

Afiliación

Geelen IGP; Department of Internal Medicine/Hematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Thielen N; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Janssen JJWM; Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands.
Levin MD; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Hoogendoorn M; Department of Internal Medicine/Hematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Visser O; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.
Cornelissen JJ; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Westerweel PE; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Eur J Haematol ; 99(4): 381-382, 2017 10.

Article en En | MEDLINE | ID: mdl-28718971

Asunto(s)

Leucemia Mielógena Crónica BCR-ABL Positiva; Organización Mundial de la Salud; Humanos; Mesilato de Imatinib; Leucemia Mieloide de Fase Crónica

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Organización Mundial de la Salud / Leucemia Mielógena Crónica BCR-ABL Positiva Límite: Humans Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google